Research Trials

If you have any questions or are interested in participating in one of our clinical research studies, please call us at 402.955.2691 or email us at clinicaltrials@nebraskacancer.com.

  • Cancer Type:

  • Biomarker:

  • Phase:

  • Keyword:

  • PUMA-ALI-4201

    A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

    Cancer Type: SCLC

    Lines of Therapy: 3, 2

    Phase: 2

    View Details on ClinicalTrials.gov

  • D516KC00001 (Tropion-Lung 15)

    A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

    Cancer Type: NSCLC

    Lines of Therapy: 2

    Biomarkers: EGFR

    Phase: 3

    View Details on ClinicalTrials.gov

  • D7632C00001 TROPION, Lung 10

    Phase 3 Randomized Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig or Rilvegostomig Monotherapy vs Pembrolizumab Monotherapy for the 1st line treatment of Locally advanced or metastatic NonSquamous NSCLC with High PDL1 Expression and without actionable mutations

    Cancer Type: NSCLC

    Lines of Therapy: 1

    Phase: 3

    View Details on ClinicalTrials.gov

  • CO44657 (pionERA)

    A Phase III Randomized, Open Label Study Evaluating the Efficacy and Safety of Girecestrant compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with ER+, Her2- Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy

    Cancer Type: BREAST

    Lines of Therapy: 1

    Biomarkers: HR+, HER2-, ESR1

    Phase: 3

    View Details on ClinicalTrials.gov

  • GO45434

    Phase II, Open-Label, Multicenter Study To Evaluate The Optimization Of The Cytokine Release Syndrome Profile For Glofitamab In Combination With Gemcitabine Plus Oxaliplatin In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Cancer Type: Lymphoma

    Phase: 2

    View Details on ClinicalTrials.gov

  • D9260C00003 (Tropion-Breast-06)

    A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

    Cancer Type: BREAST

    Lines of Therapy: 2

    Biomarkers: HR-positive, HER2 IHC 0

    Phase: 3

    View Details on ClinicalTrials.gov

  • GO45322

    A PHASE II PROSPECTIVE, OPEN-LABEL SAFETY STUDY OF INAVOLISIB AND FULVESTRANT WITH OR WITHOUT PALBOCICLIB IN PARTICIPANTS WITH PIK3CA-MUTATED HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER AND TYPE 2 DIABETES

    Cancer Type: BREAST

    Lines of Therapy: 2 or 3

    Biomarkers: HR+, HER2- , PIK3CA

    Phase: 2

  • Tempus: Gemini TP-CA-002 (CRC - Surveillance)

    Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients with CRC using NGS Assays

    Cancer Type: Colorectal

    Phase: Observational

    View Details on ClinicalTrials.gov

  • TAS-CP383-01

    A MULTI-CENTER, OPEN LABEL, PHASE 1/2 STUDY OF CP-383, AN ORAL DUAL DHODH AND TEAD4 INHIBITOR, IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

    Cancer Type: Solid tumor

    Lines of Therapy: 2

    Biomarkers: CREBBP, EP300m FAT1

    Phase: 1

    View Details on ClinicalTrials.gov

  • TER-2013-C01

    A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    Cancer Type: Solid tumor

    Biomarkers: AKT, PI3K, PTEN

    Phase: 1

    View Details on ClinicalTrials.gov

Purpose   •   Innovation   •   Relationship   •   Excellence

#caringforthegoodlife

© 2026 Nebraska Cancer Specialists  •  Privacy Policy  •  design by Chip Thompson

Meet DOT.
Skip to content